Mumbai:Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that the USFDA has granted its subsidiary an approval for its application for Nicardipine Hydrochloride Injections.
These Nicardipine Hydrochloride Injections are available as 25 mg/10ml single use ampuls containing 2.5 mg/ml of the drug, and have annual sales of approximately USD 170 million in the US.
These injections are used for the short-term treatment of hypertension when oral therapy is not feasible or not desirable.
